Key result
Glycoprotein IIb-IIIa inhibitors improve clinical outcomes in STEMI patients undergoing primary angioplasty, though further trials are needed in the era of new oral antiplatelet therapies.
Why the study?
What is the role of glycoprotein IIb-IIIa inhibitors in the management of coronary artery disease and myocardial infarction?
What is the role of glycoprotein IIb-IIIa inhibitors in the management of coronary artery disease and myocardial infarction?
This review summarizes the indications for GP IIb-IIIa inhibitors and bivalirudin in acute coronary syndromes, emphasizing tailored use based on bleeding risk and procedural timing.
No takes yet. Share an insight, caveat, or question.
Supports tailored GP IIb-IIIa use in STEMI PCI by bleeding risk; leaves open role with modern P2Y12 inhibitors.
Giuseppe De Luca (2011) conducted a review in Coronary artery disease and myocardial infarction. Glycoprotein IIb-IIIa inhibitors was evaluated. Glycoprotein IIb-IIIa inhibitors improve clinical outcomes in STEMI patients undergoing primary angioplasty, though further trials are needed in the era of new oral antiplatelet therapies.